TRIESENCE

Peak

triamcinolone acetonide

NDAINTRAVITREALINJECTABLEPriority Review
Approved
Nov 2007
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
8

Mechanism of Action

Corticosteroid Hormone Receptor Agonists

Pharmacologic Class:

Corticosteroid

Clinical Trials (5)

NCT04598542Phase 1Completed

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

Started Oct 2020
NCT02294656Phase 1Completed

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

Started Nov 2014
4 enrolled
CYSTOID MACULAR EDEMA
NCT00853905Phase 2/3Completed

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

Started Feb 2009
77 enrolled
Glaucoma
NCT00449072Phase 4Completed

Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

Started Mar 2007
299 enrolled
Rhinitis, Allergic, Perennial
NCT00476918Phase 1Unknown

Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema

Started Jul 2006
60 enrolled
Diabetic RetinopathyDiabetic Macular Edema

Loss of Exclusivity

LOE Date
Dec 17, 2029
46 months away
Patent Expiry
Dec 17, 2029

Patent Records (2)

Patent #ExpiryTypeUse Code
8211880
Mar 10, 2029
U-1257
8128960
Dec 17, 2029
Product